Analyzing MRI Contrast Clearance for Glioma Grading and Genotyping
MRI Contrast Clearance Analysis for Prediction of Grading and Genotyping in Gliomas
This study is testing if MRI scans can help doctors better understand and classify gliomas, the most common type of brain tumor, by looking at how the contrast material clears from the brain.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Sex | All |
| Sponsor | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing) |
| Trial ID | NCT06018870 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on gliomas, the most common primary brain tumors, and aims to analyze MRI contrast clearance to improve glioma grading and genotyping. Patients diagnosed with glioma will undergo MRI scans with delayed contrast sequences, followed by a series of image processing steps including registration and histogram analyses. The study will evaluate the relationship between MRI parameters and essential molecular markers such as IDH mutation status and 1p/19q codeletion. The goal is to determine if MRI contrast clearance can provide significant insights into glioma classification and treatment planning.
Who should consider this trial
Good fit: Ideal candidates include patients with brain lesions diagnosed as gliomas who have not yet received antitumor therapy.
Not a fit: Patients with WHO grade 1 gliomas or other non-glioma brain tumors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the accuracy of glioma grading and genotyping, leading to better treatment strategies and patient outcomes.
How similar studies have performed: While there is limited data on MRI contrast clearance specifically for glioma grading, similar imaging techniques have shown promise in other tumor types.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with brain space -occupying lesions, have not yet undergone antitumor therapy; * MRI with T1-contract delayed sequence was performed less than 2 weeks before surgery; * Definite histopathologic diagnosis of glioma. Exclusion Criteria: * WHO 1 gliomas and other non-glioma brain tumors; * Poor image quality and heavy artifact affect the subsequent image processing.
Where this trial is running
Chongqing, Chongqing
- Sang Zifan — Chongqing, Chongqing, China (Recruiting)
Study contacts
- Study coordinator: Zifan Sang, M.M
- Email: 952034224@qq.com
- Phone: +8618379873389
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.